TCGA-E2-A1IJ-01A-11R-A144-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.540
- ALLOGRAFT_REJECTION+0.470
- IL6_JAK_STAT3_SIGNALING+0.450
- COAGULATION+0.440
- INFLAMMATORY_RESPONSE+0.430
- APICAL_SURFACE+0.420
- KRAS_SIGNALING_UP+0.420
- APICAL_JUNCTION+0.380
- MYOGENESIS+0.380
Top 10 suppressed
- MYC_TARGETS_V1-0.720
- E2F_TARGETS-0.710
- MYC_TARGETS_V2-0.690
- G2M_CHECKPOINT-0.650
- OXIDATIVE_PHOSPHORYLATION-0.590
- MTORC1_SIGNALING-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.480
- DNA_REPAIR-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- MITOTIC_SPINDLE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.954 |
| 2 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.945 |
| 3 | 20020074.LumA | — | A | 0.943 |
| 4 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.937 |
| 5 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.936 |
| 6 | SRR2771286 | — | — | 0.936 |
| 7 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.934 |
| 8 | SRR35579818 | — | A | 0.934 |
| 9 | TCGA-AC-A3HN-01A-11R-A213-07 | — | A | 0.933 |
| 10 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.420 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |